Glyx Therapeutics to Attend Deeptech Connect 2025 in Paris
November 2025 — Amiens, France
Glyx Therapeutics will participate in Deeptech Connect, taking place at Le Centquatre in Paris in November 2025. As a flagship gathering for France’s deeptech ecosystem, the event provides a direct channel to engage investors, industrial partners, and technology transfer stakeholders as Glyx advances its Seed round and prepares its lead candidate for clinical proof-of-concept.
What Is Deeptech Connect
Deeptech Connect is a major French platform dedicated to connecting science-driven startups with the capital and partners needed to scale breakthrough innovation. Each edition brings together venture funds, corporate partners, research institutions, and public investment bodies to source and structure high-value collaboration opportunities.
Hosted at Le Centquatre, a landmark innovation venue in Paris, the event combines curated one-to-one meetings, pitch sessions, expert-led conferences, and an innovation showcase. This format makes it a focal point for investment sourcing and partnering across biotech, medtech, and adjacent deeptech sectors.
Why This Event Matters for Glyx
Glyx Therapeutics is developing, a first-in-class, orally available, brain-penetrant small molecule targeting the tau protein, the primary pathological driver of tauopathies and Alzheimer’s disease. With in vivo proof of concept established in the rTg4510 tauopathy mouse model, confirmed blood-brain barrier penetration, and a favorable early safety profile, the program stands at a key value inflection point.
Deeptech Connect 2025 supports two strategic priorities for the company:
- Investor engagement — connecting with venture funds, business angels, and family offices to accelerate the ongoing €5M Seed round.
- Industrial partnering — initiating discussions with pharmaceutical partners around the company’s staged, indication-split licensing model, spanning rare tauopathies and Alzheimer’s disease.
These conversations align with Glyx’s de-risked development strategy, centered on advancing Mal16diS through a Phase 0 (eIND) study to accelerate time-to-clinic while optimizing capital efficiency.
Event Details
- Dates: 4th November 2025
- Location: Le Centquatre, Paris, France
- Format: Curated one-to-one meetings, pitch sessions, conferences, and innovation showcase
- Focus: Deeptech investment, industrial partnering, and technology transfer
Meet Us at Deeptech Connect
Investors and partners attending Deeptech Connect 2025 are invited to schedule a meeting with the Glyx Therapeutics team. These discussions offer an opportunity to review our preclinical data package, our development roadmap toward the first in human study, and our licensing strategy under confidentiality.
We look forward to connecting with the deeptech community in Paris and advancing the development of differentiated therapeutic solutions for patients affected by tauopathies and Alzheimer’s disease.
